Aging Clinical and Experimental Research

, Volume 24, Issue 1, pp 85–96 | Cite as

Differing age related trajectories of dysfunction in several organ systems in opiate dependence

  • Albert Stuart ReeceEmail author
Original Article


Background: Several lines of evidence suggest that the multisystem disease seen in drug addicts may reflect acceleration of underlying degenerative or ageing processes. Patients presenting for management of their clinical opiate substance use disorder (SUD) were therefore compared with general medical non-SUD (N-SUD) patients. Methods: Differences in dental, psychiatric and hair graying indices at both temple and vertex were studied and combined with principal component (PC) analysis. Arcsinh transformation of the data were considered, as this improved the normality of the parameter distributions. Results: 95 opiate dependent SUD and 32 N-SUD patients were studied. The mean (±SD) ages were 33.47±7.98 vs 57.81±17.13 years and sex was 75.8% and 63.6% male (p — n.s.) in the SUD and N-SUD groups respectively. The addicted population was more severe as a function of age on all indices (p<0.05). The arcsinh transformation of PC1+PC2 was significantly different by addiction status both as a category on its own and after interaction with age (both p<0.0005), and was associated with a calculated 22.3% age advancement at 60 years of age. Interactions between age, and PC’s of opiate and inhaled intoxicant dose and duration of exposure were highly significant (p<0.01). Tobacco, cannabis, heroin and methadone dose and/or duration of exposure were significantly related to the identified physiological deficit both alone, and as interactions with each other and with age (most interactions p<0.01). Conclusions: These findings have implications for understanding the pathophysiology of drug addiction and imply that the high rate of morbidity seen in drug dependent patients may be related to underlying subclinical ager related changes, choice of opiate pharmacotherapeutic agent, considerations of duration of treatment, and conversely for the pathophysiology of the development of age related disease.

Key words

Ageing cannabis hair graying heroin methadone opiate addiction tobacco 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gottshcalk LA, McGuire FL, Heiser JF, Dinovo EC, Birch H. Drug abuse deaths in nine cities: A survey report. In: National Institute of Drug Abuse, Ed. Bethesda, Maryland, USA: National Institutes of Health; 1979: pp 1–189.Google Scholar
  2. 2.
    Braunwald E, Fauci AS, Kasper DL et al, Eds. Harrison’s Principles of Internal Medicine, 15th Ed. New York: McGraw Hill; 2001.Google Scholar
  3. 3.
    Soueif M. The use of cannabis in Egypt: a behavioural study. Bull Narcotics 1971; 33: 17–28.Google Scholar
  4. 4.
    Darke S, Kaye S, Duflou J. Systemic disease among cases of fatal opioid toxicity. Addiction 2006; 101: 1299–305.PubMedCrossRefGoogle Scholar
  5. 5.
    Kim TW, Alford DP, Malabanan A, Holick MF, Samet JH. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend 2006; 85: 258–62.PubMedCrossRefGoogle Scholar
  6. 6.
    Steingrimsson E, Copeland NG, Jenkins NA. Melanocyte stem cell maintenance and hair graying. Cell 2005; 121: 9–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Reece AS. Hair graying in substance addiction. Arch Dermatol 2007; 143: 116–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Hser YI, Gelberg L, Hoffman V, Grella CE, McCarthy W, Anglin MD. Health conditions among aging narcotics addicts: medical examination results. J Behav Med 2004; 27: 607–22.PubMedCrossRefGoogle Scholar
  9. 9.
    Kertesz SG, Pletcher MJ, Safford M et al. Illicit drug use in young adults and subsequent decline in general health: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Drug Alcohol Depend 2007; 88: 224–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Rosen D, Smith ML, Reynolds CF 3rd. The prevalence of mental and physical health disorders among older methadone patients. Am J Geriatr Psychiatr 2008; 16: 488–97.CrossRefGoogle Scholar
  11. 11.
    Mohammadi A, Darabi M, Nasry M, Saabet-Jahromi MJ, Malek-Pour-Afshar R, Sheibani H. Effect of opium addiction on lipid profile and atherosclerosis formation in hypercholesterolemic rabbits. Exp Toxicol Pathol 2009; 61: 145–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Howard AA, Floris-Moore M, Arnsten JH et al. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis 2005; 40: 1492–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Howard AA, Floris-Moore M, Lo Y, Arnsten JH, Fleischer N, Klein RS. Abnormal glucose metabolism among older men with or at risk of HIV infection. HIV Med 2006; 7: 389–96.PubMedCrossRefGoogle Scholar
  14. 14.
    McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001; 6: 111–23.CrossRefGoogle Scholar
  15. 15.
    Pillai R, Nair BS, Watson RR. AIDS, drugs of abuse and the immune system: a complex immunotoxicological network. Arch Toxicol 1991; 65: 609–17.PubMedCrossRefGoogle Scholar
  16. 16.
    Franceschi C, Bonafe M, Valensin S et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann NY Acad Sci 2000; 908: 244–54.PubMedCrossRefGoogle Scholar
  17. 17.
    Franceschi C, Monti D, Sansoni P, Cossarizza A. The immunology of exceptional individuals: the lesson of centenarians. Immunol Today 1995; 16: 12–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Sadeghian S, Darvish S, Davoodi G et al. The association of opium with coronary artery disease. Eur J Cardiovasc Prev Rehabil 2007; 14: 715–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Gutstein HB, Akli H. Opioid Analgesics. In: Hardman JG et al, Eds. Goodman & Gilman’s the Pharmacological Basis of Therapeutics. New York: McGraw Hill; 2001: pp 569–620.Google Scholar
  20. 20.
    Noonan MA et al. Regulation of adult neurogenesis by cannabinoids. Chemistry Today 2006; 24: 84–8.Google Scholar
  21. 21.
    Eisch AJ, Mandyam CD. Drug dependence and addiction, II: Adult neurogenesis and drug abuse. Am J Psychiatry 2004; 161: 426.PubMedCrossRefGoogle Scholar
  22. 22.
    Raaijmakers MH, Scadden DT. Divided within: heterogeneity within adult stem cell pools. Cell 2008; 135: 1006–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Edelberg JM, Ballard VL. Stem Cell Review Series: Regulating highly potent stem cells in aging: environmental influences on plasticity. Aging Cell 2008; 7: 599–604.PubMedCrossRefGoogle Scholar
  24. 24.
    Reece AS, Davidson P. Deficit of circulating stem — progenitor cells in opiate addiction: a pilot study. Substance abuse treatment, prevention, and policy. 2007; 2: 19–28.PubMedCrossRefGoogle Scholar
  25. 25.
    Reece A.S. Chronology and patterns of psychiatric morbidity in substance dependent and medical patients. Australasian Psychiatry 2009; 17: 170–1.CrossRefGoogle Scholar
  26. 26.
    Reece AS. Dentition of addiction in Queensland: poor dental status and major contributing drugs. Australian Dental Journal 2007; 52: 144–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Sarkar D. Lattice: Multivariate Data Visualization with R. In Gentleman R, Hornik K, Parmigiani G, Eds. Springer; 2008.Google Scholar
  28. 28.
    Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell 2005; 120: 483–95.PubMedCrossRefGoogle Scholar
  29. 29.
    Hadley EC, Lakatta EG, Morrison-Bogorad M, Warner HR, Hodes RJ. The future of aging therapies. Cell 2005; 120: 557–67.PubMedCrossRefGoogle Scholar
  30. 30.
    Kondratov RV, Kondratova AA, Gorbacheva VY, Vykhovanets OV, Antoch MP. Early aging and age-related pathologies in mice deficient in BMAL1, the core component of the circadian clock. Genes Dev 2006; 20: 1868–73.PubMedCrossRefGoogle Scholar
  31. 31.
    Reece AS. Chronic hepatitis as an important contributor to the immunosenescence of parenteral drug addiction. Addiction Biology 2008; 14: 214–26.PubMedCrossRefGoogle Scholar
  32. 32.
    Reece AS. Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers. Immun Ageing 2007; 4: 6–15.PubMedCrossRefGoogle Scholar
  33. 33.
    Franceschi C, Capri M, Monti D et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007; 128: 92–105.PubMedCrossRefGoogle Scholar
  34. 34.
    Wikby A, Ferguson F, Forsey R et al. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci 2005; 60: 556–65.PubMedCrossRefGoogle Scholar
  35. 35.
    Cooper OB, Brown TT, Dobs AS. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis 2003; 37 (Suppl 2): S132–6.CrossRefGoogle Scholar
  36. 36.
    Gopinath SD, Rando TA. Stem Cell Review Series: Aging of the skeletal muscle stem cell niche. Aging Cell 2008; 7: 590–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Nishimura EK, Jordan SA, Oshima H et al. Dominant role of the niche in melanocyte stem-cell fate determination. Nature 2002; 416: 854–60.PubMedCrossRefGoogle Scholar
  38. 38.
    Choksi KB, Papaconstantinou J. Age-related alterations in oxidatively damaged proteins of mouse heart mitochondrial electron transport chain complexes. Free Radic Biol Med 2008; 44: 1795–805.PubMedCrossRefGoogle Scholar
  39. 39.
    Zimmerman AM, Zimmerman S, Raj AY. Effects of Cannabinoids on spermatogenesis in mice. In Nahas GG, Sutin KM, Harvey DJ, Agurell S, Eds. Marihuana and medicine. Totowa, NJ, USA: Humana Press; 1999: pp 347–58.CrossRefGoogle Scholar

Copyright information

© Springer Internal Publishing Switzerland 2012

Authors and Affiliations

  1. 1.School of Psychiatry and Clinical NeurosciencesUniversity of Western AustraliaBrisbaneAustralia

Personalised recommendations